Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

Analysis of Primary Endpoint for Phase 3 Registration Trial No Later Than

July 2008

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today reported its financial results for the fourth quarter and year end 2007. For the quarter and year ended December 31, 2007, the Company reported net losses of $7.8 million, or $0.21 per share, and $43.1 million, or $1.28 per share, respectively, compared to $10.2 million, or $0.35 per share, and $40.5 million, or $1.49 per share, for the same periods in 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

"It is with great excitement and anticipation that we begin 2008 and approach the end of our Phase 3 clinical trial of Specifid(TM) (mitumprotimut-T, formerly FavId(R))," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We are in the process of data collection and are on schedule for data cut off in April and completion of data analysis no later than July. The rate of disease progression continues to be very slow and we believe we have enrolled an optimal patient population to maximize prospects for demonstrating a clinical benefit in our Phase 3 trial."

Fourth Quarter and Year End 2007 Financial Review

Research and development expense was approximately $7.8 million and $34.9 million for the fourth quarter and year ended December 31, 2007, respectively, compared to approximately $7.7 million and $31.1 million for the same periods in 2006. The increase is primarily due to operating expenses, including salaries and stock-based compensation, associated with our commercial-scale manufacturing facility, and consulting and outside services to support our Specifid Phase 3 clinical trial. Total st
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... May 9, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... or "AOB"), a pharmaceutical company dedicated to improving ... a broad range of prescription and over–the-counter ("OTC") ... quarter ended March 31, 2011. ...
... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
... 9, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of small-molecule therapeutics for the treatment of serious diseases, ... first quarter ended March 31, 2011. "Results from our ... with allopurinol demonstrate lesinurad,s potential to bring relief to ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2011 Financial Results 2American Oriental Bioengineering Reports First Quarter 2011 Financial Results 3American Oriental Bioengineering Reports First Quarter 2011 Financial Results 4American Oriental Bioengineering Reports First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6
(Date:4/23/2014)... group decision increases with the abundance of brains involved ... variety of factors as often happens in life ... groups actually tend to make more accurate decisions while ... pieces of information. , The findings present a significant ... the "wisdom of crowds," wherein individual observations even ...
(Date:4/23/2014)... newly coined term for novels and films which focus on ... Copenhagen shows how these fictions serve as a mental laboratory ... change and imagine other living conditions. , "Global warming ... atmosphere; it is also a cultural phenomenon in which meaning ... films we see. And there are so many of them ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... More than 450 world experts from 60 countries will ... DNA "barcoding" - a rapidly growing international initiative to develop ... Earth. The Fourth International Barcode of Life Conference ... from Wednesday 30 November to Saturday 3 December. ...
... years ago, two teams of explorers raced to be the first ... South Pole on December 14, 1911. , Thirty-three days later ... Falcon Scott arrived at the Pole in second place. At ... by Douglas Mawson was searching for the South Magnetic Pole. ...
... surface of an implant such as a new hip or ... and researchers at the University of Gothenburg, Sweden, can now ... are presented in the International Journal of Nanomedicine . ... of the most common reasons for an implant being rejected," ...
Cached Biology News:Seaweed hotspots, illegal logging, and discovering new species under the desert 2Seaweed hotspots, illegal logging, and discovering new species under the desert 3Seaweed hotspots, illegal logging, and discovering new species under the desert 4Climate change stunting growth of century-old Antarctic moss shoots 2Cobblestones fool innate immunity 2
APG5 autophagy 5-like (S. cerevisiae)...
...
Griess Reagent component for determination of nitrite in aqueous solutions....
... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
Biology Products: